Alan T. Savitz

发表

Orexin Receptor Antagonists Differ from Standard Sleep Drugs by Promoting Sleep at Doses That Do Not Disrupt Cognition

Steven V. Fox, Xiaohai Wang, Jason M. Uslaner, 2013, Science Translational Medicine.

Orexin receptor antagonist-induced sleep does not impair the ability to wake in response to emotionally salient acoustic stimuli in dogs

Steven V. Fox, J. Uslaner, J. Renger, 2014, Front. Behav. Neurosci..

Identification of MK-8133: An orexin-2 selective receptor antagonist with favorable development properties.

J. Renger, P. Coleman, A. Gotter, 2015, Bioorganic & medicinal chemistry letters.

The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold

Steven V. Fox, J. Uslaner, J. Renger, 2013, BMC Neuroscience.

Quantitative Electroencephalography Within Sleep/Wake States Differentiates GABAA Modulators Eszopiclone and Zolpidem From Dual Orexin Receptor Antagonists in Rats

Steven V. Fox, J. Uslaner, J. Renger, 2013, Neuropsychopharmacology.

High-resolution peripheral quantitative computed tomography and finite element analysis of bone strength at the distal radius in ovariectomized adult rhesus monkey demonstrate efficacy of odanacatib and differentiation from alendronate.

Donald S. Williams, L. Duong, B. Dardzinski, 2013, Bone.

Pharmacological Validation of Candidate Causal Sleep Genes Identified in an N2 Cross

Steven V. Fox, A. Kasarskis, J. Renger, 2011, Journal of neurogenetics.

Effect of odanacatib on bone turnover markers, bone density and geometry of the spine and hip of ovariectomized monkeys: a head-to-head comparison with alendronate.

Donald S. Williams, L. Duong, B. Dardzinski, 2013, Bone.

Inhibition of Orexin Signaling Promotes Sleep Yet Preserves Salient Arousability in Monkeys.

Steven V. Fox, J. Uslaner, J. Renger, 2016, Sleep.